Login

Journal Image
CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)
ISSN (Print): 1871-5273
ISSN (Online): 1996-3181
VOLUME: 11
ISSUE: 3
DOI: 10.2174/187152712800672517      Price:  $58









Inhibitors of Catechol-O-Methyltransferase

img
Author(s): James C. Barrow
Pages 324-332 (9)
Abstract:
Since the identification of Catechol-O-Methyltransferase (COMT) by Axelrod in 1957, many inhibitors of this enzyme have been reported. While COMT inhibition may be beneficial in a number of disease states, most of the effort over the years has been directed at boosting L-DOPA concentrations as adjunct treatment for Parkinson’s disease. This review summarizes the major classes of COMT inhibitors, from early catechol and pyrogallol variants to bisubstrate inhibitors. The nitrocatechol substructure has proven to be a particularly productive scaffold, resulting in two marketed drugs and several improved drug candidates working their way through clinical trials.
Keywords:
Catechol-O-methyltransferase, COMT, dopamine, L-DOPA, Parkinson's disease, nitrocatechol, MB-COMT, SAM Binding, HPLC, DOPAC
Affiliation:
Lieber Institute for Brain Development, 336 John G. Rangos Building, 855 North Wolfe St., Baltimore, MD 21205, USA.